Lackner T E, Lau B W, Parvin C, Valdes R
St. Louis College of Pharmacy, MO.
Clin Pharm. 1988 Jun;7(6):449-53.
The effect of digoxin-like immunoreactive substance (DLIS) on serum digoxin determinations in elderly patients with normal serum creatinine concentrations was studied. Patients in the study group were over 70 years of age; the control population was under 55 years of age. All patients had serum creatinine concentrations of less than or equal to 1.5 mg/dL. Apparent digoxin content of serum samples from patients receiving digoxin and from patients in each age group who were not receiving digoxin was determined in duplicate by each of two radioimmunoassays: RIANEN (New England Nuclear), which detects DLIS, and Immophase (Corning Medical and Scientific), which is far less cross-reactive with DLIS. Results from the patients under 55 years of age were analyzed for inherent bias between the assay methods. In patients over 70 years of age, concentrations of DLIS (differences between serum digoxin concentrations measured by RIANEN and Immophase) were compared with creatinine clearance values. No DLIS was detected in sera of patients who had not received digoxin. For patients who received digoxin, nearly all apparent digoxin concentrations were within the usual therapeutic range. For patients without liver or renal failure who received digoxin, no significant difference in digoxin concentrations was observed between the RIANEN and Immophase assays in either the young (n = 17) or elderly (n = 26) patients. There was no significant increase in the difference between the RIANEN and Immophase results with decreasing creatinine clearance. In the elderly patients with normal serum creatinine concentrations, there was no evidence that measurement of serum digoxin concentration using the RIANEN and Immophase assays was compromised by DLIS.
研究了地高辛样免疫反应物质(DLIS)对血清肌酐浓度正常的老年患者血清地高辛测定的影响。研究组患者年龄超过70岁;对照组年龄在55岁以下。所有患者的血清肌酐浓度均小于或等于1.5mg/dL。采用两种放射免疫分析法对接受地高辛治疗的患者以及各年龄组未接受地高辛治疗患者的血清样本中的表观地高辛含量进行了双份测定:RIANEN(新英格兰核公司),可检测DLIS;Immophase(康宁医学与科学公司),与DLIS的交叉反应性低得多。分析了55岁以下患者两种检测方法之间的固有偏差。在70岁以上的患者中,将DLIS的浓度(RIANEN和Immophase测量的血清地高辛浓度之间的差异)与肌酐清除率值进行了比较。未接受地高辛治疗的患者血清中未检测到DLIS。对于接受地高辛治疗的患者,几乎所有表观地高辛浓度均在通常的治疗范围内。对于无肝或肾功能衰竭且接受地高辛治疗的患者,无论是年轻患者(n = 17)还是老年患者(n = 26),RIANEN和Immophase检测法测得的地高辛浓度均无显著差异。随着肌酐清除率降低,RIANEN和Immophase结果之间的差异没有显著增加。在血清肌酐浓度正常的老年患者中,没有证据表明使用RIANEN和Immophase检测法测量血清地高辛浓度会受到DLIS的影响。